Month: September 2020

879-65-2, 2-Quinoxalinecarboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

879-65-2, General procedure: The tail group containing monomer, dimer ortrimer (0.266 mmol) was dissolved in methanol (25 mL), to which Pd/C-10% (60mg) was added at 0oC under nitrogen with stirring. The reactionmixture was hydrogenated at room temperature and atmospheric pressure for 4 h.The catalyst was removed over Kieselguhr and the solvent was removed underreduced pressure to give the amine, which was dissolved in DMF (1 mL, dry). Theappropriate head group carboxylic acid (0.266 mmol) was dissolved in DMF (1 mL,dry) to which HBTU (260 mg, 0.685 mmol) and triethylamine (50 muL) were added tothe reaction mixture at room temperature with stirring and the reaction mixturewas left standing at room temperature overnight. The product was purified byHPLC (no work up required). Fractions containing the product were collected andfreeze dried to give the required product.

The synthetic route of 879-65-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Scott, Fraser J.; Puig-Sellart, Mireia; Khalaf, Abedawn I.; Henderson, Catherine J.; Westrop, Gareth; Watson, David G.; Carter, Katharine; Grant, M. Helen; Suckling, Colin J.; Bioorganic and Medicinal Chemistry Letters; vol. 26; 15; (2016); p. 3478 – 3486;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

55687-05-3, 2,5-Dichloroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

55687-05-3, EXAMPLE 5 Preparation of N-(5-chloro-2-quinoxalinyl)benzofuran-5-sulfonamide In a manner similar to Example 4, the reaction mixture from benzofuran-5-sulfonamide (397 mg, 2.01 mmol), sodium hydride (60%, 315 mg, 7.9 mmol) and 2,5-dichloroquinoxaline (600 mg, 3.01 mmol) was poured carefully into water and washed with hexanes. The hexane-free aqueous was acidified to a pH of 1-2 by the addition of 5N hydrochloric acid solution and the resulting precipitate was collected and dried. This precipitate was washed with methylene chloride and the solid obtained by evaporation of the filtrate was purified by radial silica gel chromatography (EtOAc/hexanes) followed by silica gel flash chromatography (diethyl ether/hexanes). The resulting foam which was broken up in hexanes, collected and dried, finally under vacuum at 80 C. to yield the title product (110 mg, 15%) as a solid. Analysis of the title compound gave the following results: 1 H NMR (300 MHz, d6 -DMSO) delta7.15 (d, 1H, J=2.0 Hz, Ar-H), 7.64-8.0 (overlapping multuplets, 4H, Ar-H), 8.03 (d, 1H, J=7.3 Hz, Ar-H), 8.13 (d, 1H, J=2.0 Hz, Ar-H), 8.51 (s, 1H, Ar-H), 8.67 (s, 1H, Ar-H), 12.21 (s, 1H, exchanges with D2 O, NH); IR(KBr) 1617, 1581, 1453, 1263 and 1153 cm-1; FDMS (DMSO) m/e=359, 361 (M+). Analysis of C16 H10 ClN3 O3 S: Theory: C, 53.41; H, 2.80; N, 11.68. Found: C, 52.95; H, 2.99; N, 11.47.

As the paragraph descriping shows that 55687-05-3 is playing an increasingly important role.

Reference£º
Patent; Eli Lilly and Company; US5529999; (1996); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

148231-12-3, 5,8-Dibromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of 5,8-dibromoquinoxaline (3) (287 mg, 1.0 mmol), Pd(PPh3)2Cl2 (70 mg, 0.1 mmol), CuI (9.5 mg, 0.05 mmol) and PPh3 (26 mg, 0.1 mmol) in triethylamine/tetrahydrofuran 1:1 (20 mL) was stirred and heating until 70 C. Then, the respective terminal arylacetylene (4aeg) (2.5 mmol) dissolved in tetrahydrofuran (10 mL) was added dropwise. The reaction mixture was stirred under reflux for 20min under a nitrogen atmosphere. Cooled down to room temperature, the solution was evaporated, and the crude product was purified by a silica gel chromatography column using hexane/dichloromethane (70:30) as the eluent to afford the respective final compound 5a-g.

148231-12-3, 148231-12-3 5,8-Dibromoquinoxaline 11514763, aquinoxaline compound, is more and more widely used in various.

Reference£º
Article; Aguiar, Leonardo de O.; Junior, Adalberto S.L.; Bechtold, Ivan H.; Curcio, Sergio Fernando; Cazati, Thiago; Alves, Tiago V.; Vieira, Andre Alexandre; Journal of Molecular Liquids; vol. 296; (2019);,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (126 mg, 0.657 mmol) and 1-hydroxybenzotriazole monohydrate (89.0 mg, 0.657 mmol) were added to a methylene chloride solution (5.0 ml) of the resulting compound (165 mg, 0.438 mmol) and 3-hydroxyquinoxaline-2-carboxylic acid (125 mg, 0.657 mmol), at room temperature, and stirring was carried out at room temperature overnight. The reaction solution was poured into a 2N aqueous hydrochloric acid solution, followed by extraction with ethyl acetate, the extract was washed sequentially with water, a saturated aqueous sodium hydrogencarbonate solution, water and saline, and then the resulting organic layer was dried over anhydrous sodium sulfate. The organic layer was concentrated, the resulting residue was purified by a medium-pressure preparative liquid chromatograph (manufactured by Biotage, Inc., 25+M), the residue resulting from concentration was suspended in a mixed solvent of methylene chloride-dimethylether, and the solid substance was collected by filtration to afford the desired title compound (217 mg, yield 90%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.82 (1H, brs), 9.50 (1H, d, J=9.0 Hz), 7.86 (1H, t, J=7.0 Hz), 7.65-7.63 (2H, m), 7.49-7.36 (4H, m), 4.94-4.85 (2H, m), 3.71-3.61 (4H, m), 2.55 (3H, d, J=12.9 Hz), 1.96-1.84 (5H, m), 0.97-0.93 (6H, m). IR (KBr) cm-1: 2965, 1685, 1640, 1540, 1480, 1265. MS (ESI, m/z): 571 (M+Na)+. HRMS (ESI, m/z): 571.2075 (Calcd for C28H29FN6NaO5: 571.2081)., 1204-75-7

1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.212327-11-2,7-Bromoquinoxalin-2-amine,as a common compound, the synthetic route is as follows.

7-bromoquinoxaline-2-amine (500 mg, 2.24 mmol) and 2-bromo-1-(tetrahydro-2H-pyran-4-yl)ethan-1-one (462 mg, 2.24 mmol) were added to N-methylpyrrolidone (1 mL). After reaction under agitation at 150 C for 1 h under the protection of nitrogen, the reaction mixture was cooled to rt. Water (10 mL) was added, and EA (20 mL*2) was used for extraction. The organic phases were combined, washed with a saturated saline solution (20 mL*2), dried with anhydrous sodium sulfate, filtered, and concentrated at reduced pressure to obtain a crude compound. Isolation and purification by column chromatography (silica gel, DCM: MeOH = 30:1 as an eluant) was performed to obtain the targeted compound (120 mg, 16.2% yield, yellow solid). LC-MS (ESI): m/z (M+1) 332.14.

212327-11-2, 212327-11-2 7-Bromoquinoxalin-2-amine 15322531, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; Impact Therapeutics, Inc; CAI, Suixiong; TIAN, Ye Edward; (74 pag.)EP3567041; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1865-11-8,Methyl quinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.

General procedure: All the solids and liquids were introduced on the platform whichis inertized under argon. [Ir(cod)Cl]2 (3.4 mg; 0.005 mmol), the ligands (0.011 mmol for the bisphosphines and 0.022 mmol for the monophosphines) were automatically weighted into vials and solubilized into the chosen solvents (5 mL). Iodine solution (0.025 mmol, 12.7 mg in 2 mL of solvent) was prepared in a separated vial. The catalytic solutions were introduced into the autoclaves and the mixtures were stirred for 30 min for preparing the precatalysts. The substrate (1 mmol) was then added in each autoclave. Then, iodine in solution (0.1 mmol) was introduced. The reactors were then purged with molecular hydrogen three times and pressurized at the desired pressure of dihydrogen. The stirring was started once the desired temperature was reached. At the end of the assays, the reactors were returned at ambient temperature and depressurized. The catalytic mixtures were filtered separately through pads of silica gel. Then, GC analysis and examination of 1HNMR spectra allowed determining the conversions. The enantiomeric excesses were determined by HPLC analysis., 1865-11-8

The synthetic route of 1865-11-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Maj, Anna M.; Heyte, Svetlana; Araque, Marcia; Dumeignil, Franck; Paul, Sebastien; Suisse, Isabelle; Agbossou-Niedercorn, Francine; Tetrahedron; vol. 72; 10; (2016); p. 1375 – 1380;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

91-19-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.91-19-0,Quinoxaline,as a common compound, the synthetic route is as follows.

Bromine (3.84g, 24mmol) was added dropwise to a magnetically stirred refluxing mixture of quinoxaline (1) (390mg, 3.0mmol) and barium carbonate (1.20g, 6.1mmol) in acetonitrile (20mL). The resulting reaction mixture was heated at reflux temperature for 25h and allowed to warm to room temperature. The solvent was evaporated and the mixture was diluted with a saturated solution of sodium carbonate (10mL). The mixture was extracted with ethyl acetate (3¡Á25mL) and combined organic layers were washed with water, dried over Na2SO4 and concentrated. The residue was purified via column chromatography on silica gel (100g) by eluting with 15% EtOAc/n-hexane. The first fraction was 6-bromoquinoxaline (10) (195mg, 31%) data as before. The second fraction was 5,8-dibromoquinoxaline (12) (45mg, 5%) data as before. The third fraction was 6,7-dibromoquinoxaline (13) (50mg, 6%) data as before. The fourth fraction was 5,7-dibromoquinoxaline (11) (120mg, 14%) data as before. The fifth fraction was 5,6-dibromoquinoxaline (14) (240mg, 28%) data as before.

The synthetic route of 91-19-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Ucar, Sefa; E?siz, Selcuk; Da?tan, Arif; Tetrahedron; vol. 73; 12; (2017); p. 1618 – 1632;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

3476-89-9, 1,2,3,4-Tetrahydroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 5-(3,4,5-trimethoxyphenyl)penta-(2E,4E)-dienoyl chloride in methylene chloride (3 ml) was added dropwise to a solution of 45 mg (0.34 mmol) of 1,2,3,4-tetrahydroquinoxaline(1) in pyridine (0.5 ml) over about 5 minutes with stirring in an ice bath.. After completion of the addition, the mixture was stirred for 1 hour and water was added to conduct extraction with chloroform.. An organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure.. The resultant crude oil (254 mg) was purified by column chromatography on alumina and column chromatography on silica gel to obtain 91 mg (yield: 43%) of crude crystals of the title compound.. The crude crystals were recrystallized from chloroform-ether to obtain pale yellow fien needles. Melting point: 183-185 C. 1H-NMR (DMSO-d6, 120 C.) delta: 3.71(s,6H), 3.80(s,12H), 3.97(s,4H), 6.52(d,J=14.9 Hz,2H), 6.80(s,4H), 6.85-7.00(m,4H), 7.21-7.28(m,2H), 7.36(ddd,J=14.9,9.0,1.1 Hz,2H), 7.38-7.45(m,2H)., 3476-89-9

As the paragraph descriping shows that 3476-89-9 is playing an increasingly important role.

Reference£º
Patent; Kowa Co., Ltd.; US6340682; (2002); B1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23088-23-5,Methyl 6-Quinoxalinecarboxylate,as a common compound, the synthetic route is as follows.

To a solution of methyl quinoxaline-6-carboxylate (500 mg, 2.66 mmol) in 10 mL of THF was added sodium hydroxide (5N, 2.5 mL, 12.5 mmol) followed by methanol (2.5 mL). The reaction was stirred at room temperature overnight and then concentrated in vacuo to remove THF/MeOH. The resulting aqueous mixture was acidified with IN HCl until the pH was slightly acidic (pH = 5). The resulting solution was extracted with EtOAc (3x), and the combined organic layers were then washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The resulting white solid was used without further purification. LC-MS: 3.50 min. (M+H) = 175.16, 23088-23-5

The synthetic route of 23088-23-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK & CO., INC.; WO2006/14618; (2006); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

The resulting compound (190 mg, 0.600 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (110 mg, 0.600 mmol) to afford N-[(1S)-1-{[4-(cyclohexyloxy)piperidin-1-yl]carbonyl}-2-methylpropyl]-3-hydroxyquinoxaline-2-carboxamide (219 mg, yield 81%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.81 (1H, brs), 9.45 (1H, t, J=8.3 Hz), 7.86 (1H, d, J=8.3 Hz), 7.63 (1H, t, J=7.5 Hz), 7.39-7.36 (1H, m), 4.86 (1H, dd, J=16.1 Hz, 9.3 Hz), 3.95-3.88 (2H, m), 3.70-3.63 (1H, m), 3.39-3.27 (3H, m), 3.19-3.06 (1H, m), 2.51-2.49 (4H, m), 1.92-1.11 (11H, m), 0.95-0.92 (6H, m). IR (ATR) cm-1: 2930, 1690, 1640, 1530, 1475, 1450, 1090. MS (ESI, m/z): 455 (M+H)+. Anal. Calcd for C25H34N4O4: C, 66.06; H, 7.54; N, 12.33. Found: C, 65.77; H, 7.47; N, 12.33., 1204-75-7

As the paragraph descriping shows that 1204-75-7 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider